Robert Orenstein

Appearances

SAFETY OUTCOMES AND CONCOMITANT MEDICATION CHANGES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE BEING TREATED WITH RBX2660 FOR RECURRENT <i>CLOSTRIDIOIDES DIFFICILE</i> INFECTION
Date
May 8, 2023
BACKGROUND: Recurrent _Clostridioides difficile _infection (rCDI) is a debilitating disease associated with significant healthcare burden and low quality of life. The greatest risk factor for rCDI is a history of recurrence, although older age (≥65 years) and comorbidities also increase risk…
Presenter
Jessica Allegretti
Brigham and Women's Hospital
Speakers
Paul Feuerstadt
Whitfield Knapple
Robert Orenstein
Philippe Pinton
Jonas Pettersson
Bryan Fuchs
Samson Ng
Victoria Pokhilko
Alexander Sheh
Sahil Khanna
Mayo Clinic